Clinical trial · Interventional
Study of Colorectal Cancer Screening Options
NCT05987709CI-TRIAL-00099075completedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators propose to evaluate Guardant Health's commercially available colorectal cancer screening assay(Guardant SHIELD) in individuals who are not up to date with CRC screening.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colon Cancer | Malignant Colon Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| GuardantSHIELD Blood Test | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- OTHER
- label
- Guardant Shield Blood Test
- description
- Patients will have the Guardant Shield blood test for colorectal cancer screening.
- interventionNames
- Diagnostic Test: GuardantSHIELD Blood Test
- type
- NO_INTERVENTION
- label
- Standard of Care
- description
- Patients will have standard of care, which is a reminder to do their FIT test for colorectal cancer screening
Primary outcomes (1)
- measure
- Assess Colorectal Cancer Screening Completion
- timeFrame
- Within 3 months of patient identification
- description
- Assess the percentage who received any CRC screening test (blood draw, FIT or FIT-DNA, or flexible sigmoidoscopy or colonoscopy) within 3 months of eligibility determination among eligible individuals in the blood test and usual care groups.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 45 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Age 45-75 * Received a FIT test in the last 3-9 months yet did not return their FIT * Upcoming appointment or willing to reschedule an appointment at KPNW within 2 - 6 weeks * Able and willing to provide informed consent if in the intervention arm Exclusion Criteria: * On KPNW's do not contact list * Having a legal authorized representative * Non-English speakers
References
Publications (1)
- DERIVEDCoronado GD, Jenkins CL, Shuster E, Johnson C, Amy D, Cook J, Sahnow S, Zepp JM, Mummadi R. Blood-based colorectal cancer screening in an integrated health system: a randomised trial of patient adherence. Gut. 2024 Mar 7;73(4):622-628. doi: 10.1136/gutjnl-2023-330980. PMID 38176899